Answers are grounded in this paper and cite their sources.
Tibolone is a synthetic steroid widely used for the treatment of menopausal symptoms and prevention of osteoporosis. Unlike conventional menopausal hormone therapy (MHT), tibolone is converted into metabolites with estrogenic, progestogenic and androgenic activity, and their relative availability may differ among tissues. Intracrinology, whereby circulating steroid precursors are locally converted into active hormones or inactive metabolites within target tissues, provides a potential framework for understanding these differential effects. This study aimed to critically examine the intracrinological basis of tibolone pharmacology and assess the extent to which tissue-specific metabolism may contribute to its differential clinical effects across estrogen-sensitive tissues. A critical narrative review of experimental studies, randomized clinical trials and systematic reviews was conducted to evaluate tibolone metabolism and the distribution and activity of its metabolites in major target tissues, including breast, uterus, vagina, brain and bone. Tibolone acts predominantly as a prodrug and is converted into three active metabolites: the estrogenic compounds 3α-hydroxytibolone and 3β-hydroxytibolone, and the Δ4-isomer, which has progestogenic and androgenic properties. Experimental evidence indicates that tissue-specific differences in enzyme expression, sulfation, desulfation and possibly membrane transport may influence the local balance and availability of these metabolites. In breast and uterine tissues, preclinical studies suggest a predominance of sulfated metabolites, a pattern compatible with comparatively limited availability of unconjugated estrogenic metabolites. In bone and vaginal tissue, clinical benefits are compatible with sufficient local or systemic estrogenic activity. Evidence relating intracrinology to effects in the central nervous system remains limited and largely indirect. Across tissues, clinical outcomes are influenced by population characteristics, underlying pathology, dose and concomitant treatment, and do not directly establish the proposed metabolic mechanisms. Intracrinology provides a biologically plausible framework for understanding the tissue-selective effects of tibolone. However, clinical findings are largely compatible with, rather than confirmatory of, this mechanism, and the balance of benefits and risks appears to vary according to tissue, clinical context and individual patient characteristics. Tibolone is a treatment used to relieve menopausal symptoms and protect bone health. Unlike standard menopausal hormone therapy, its effects may differ between tissues, which can influence both its benefits and risks. This article explores whether intracrinology, the local conversion of hormone precursors into active hormones within each tissue, may contribute to these differences. We reviewed evidence from laboratory studies, animal model studies, human tissue studies, clinical trials and systematic reviews. Tibolone is converted into active metabolites with estrogenic, progestogenic and androgenic effects. Experimental evidence suggests that local enzyme activity, sulfation, desulfation and possibly transport processes may influence the balance of these metabolites in different tissues. Clinical benefits are well established in bone and vaginal tissues, whereas effects in the breast, uterus and brain are more variable and depend on the clinical context. Overall, intracrinology provides a useful biological framework for interpreting some of tibolone’s tissue-dependent effects. However, direct human evidence linking local metabolism to clinical outcomes remains limited, and intracrinology should not be considered the sole explanation for tibolone’s benefits and risks.
No takes yet. Share an insight, caveat, or question.
Melo et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: